Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
    • Contact Us
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
    • MIS Systems
    • Online Data Verification
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
Home > Articles by: Murtaza Awan

Author: Murtaza Awan

Holding of Khuli E-Kachehri

Murtaza Awan General September 27, 2021December 29, 2021Other

Holding of 12th Khuli E-Kachehri.

12-e-KachehriDownload

Minutes Of 312th Meeting Of Registration Board Held On 14-16th September, 2021.

Murtaza Awan Registration Board September 14, 2021January 13, 2022PER

Minutes Of 312th Meeting Of Registration Board

PDF FileDownload

Inspection Of Manufacturers Abroad For Registration Of Finished Drugs

Murtaza Awan Drugs September 10, 2021December 29, 2021PER

Policy Board of the Drug Regulatory Authority of Pakistan (DRAP) in its various meetings have already exempted inspection of manufacturer abroad in certain scenarios.

Mfg-abroadDownload

Drug Product Recall: Delmol Suspension (Batch #151) by M/S Delta Pharma (Pvt) Ltd Nowshera

Murtaza Awan Recall Alerts September 7, 2021February 23, 2022QA & LT

Delmol Suspension Batch No.151 Mfg Date 05-2021, Exp Date 05-2023 Manufactured By M/S Delta Pharma (Pvt) Ltd Nowshera

PDf FIleDownload

Notification F.No.4-2/2017-DD (H&OTC)

Murtaza Awan Alternative Medicines September 2, 2021December 30, 2021HOTC

Guidelines for holder of Drug Manufacturing License, to manufacture the Alternative Medicines and Nutritional Products & Food Supplements and Probiotics.

PDF File Download

Notification F.No.8-3/2019-H&OTC

Murtaza Awan Alternative Medicines September 2, 2021December 29, 2021HOTC

Guidelines for manufacturing of Alternative Medicines, Health Products and Probiotic by the DML holders.

notificationDownload

Conduct Of Clinical Trials Guidelines (v2.0) Stake holders are invited for comments to be submitted within 15 days to email: drap.pharmacy@gmail.com

Murtaza Awan Clinical Trials September 2, 2021December 30, 2021Pharmacy Services

This is the second edition of these guidelines. The first edition was published on 08th November, 2019.

PDF FileDownload

List Of Required Sops At BA/BE Studies Center

Murtaza Awan Clinical Trials September 1, 2021December 30, 2021Pharmacy Services

The following is an example list of the standard operating procedures (SOPs) that should be used at BA/BE Studies Center.

PDF FileDownload

Process Flow of Clinical Trials

Murtaza Awan Clinical Trials August 31, 2021January 6, 2022Pharmacy Services

Process Flow chart for processing of applications for Clinical studies  

FileDownload

Online Submission of Licence Application of Medical Devices

Murtaza Awan General, Medical Devices August 31, 2021January 6, 2022Medical Devices

Online Submission of Licence Application of Medical Devices

PDF FileDownload
  • ← Previous
  • Next →

Archives

  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • May 2019
  • February 2019
  • January 2019
  • December 2018
  • October 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • February 2018
  • November 2017
  • October 2017
  • July 2017
  • June 2017
  • May 2017
  • March 2017
  • November 2016
  • June 2016
  • March 2016
  • May 2014
  • March 2014
  • January 2014
  • October 2013
  • August 2013
  • April 2013
  • October 2012
  • July 2012
  • March 2012
  • February 2002

Meta

  • Log in

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:00AM to 04:00PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem